Clinical Trial Search

Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…

Primary: Number of Participants With Abscess Resolution — 11; 9 Participants

Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68

Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…

Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants

Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants

Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…

Primary: Recurrence Rates of Abscesses — 4; 14 participants

Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants

Primary: Satisfaction of Discharge Criteria — 15; 14 participants

Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants

Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant

Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants

Primary: Skin Abscess Resolution — 4; 3 participants

Primary: Early Clinical Response — 306; 303 Participants

Primary: Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator — 94.6; 90.1; 91.1…

Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…

Primary: Investigator's Assessment of Clinical Response in the ITT (Intent-to-treat) Population at Follow-up — 57; 50; 53 Participants

Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants

Primary: Change in Microbiome — 5.46; 3.88 colony forming units per ml (CFU/ml)

Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318

Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance

Primary: Number of Side-effects — 4; 2 Participants

Primary: Treatment Failures — 9; 4 participants — p=0.25

Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71

Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants

Primary: Treatment Failures at 7 Days — 15; 27 participants

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Hospital Admission Rate at Initial Episode of Care — 60; 27; 96; 126 Participants — p=<0.001

Primary: Number of Infection-related Total Admitted Hospital Days — 4.8; 3.2 Days — p=0.003